Long-acting injectable cabotegravir (CAB-LA) is a promising new option for HIV prevention. In 2020, early results from two trials—HPTN 083 and HPTN 084—showed CAB-LA was safe and highly effective at preventing HIV when compared to daily oral TDF/FTC (Truvada) in men who have sex with men (MSM), transgender (TG) women and cisgender women. Now what? What questions remain unanswered and what support is needed now to make the growing range of prevention options feasible choices for people who may want and need them?
CAB-LA is a Highly Effective HIV Prevention Option; Now what?
AMP Study FAQ
From the two trial networks conducting the AMP Study, this document provides answers to commonly asked questions about the VRC01 antibody, details on the study design and more.
AVAC’s World AIDS Day 2020 Letter to the World
On World AIDS Day 2020, AVAC hones in on three things that are essential advocacy priorities for the present moment and in 2021.
• Program for choice.
• Pay for the healthcare workforce to achieve health equity.
• Pursue just, equitable access for COVID-19 vaccines, therapeutics and community-led prevention.
Biomedical HIV Prevention Trials: Results, milestones and more
This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.
Another version of this graphic is available here (same content, different visual Treatment U=U).
The Next-Generation of Biomedical Prevention: Now What
Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.
Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring
On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.
Global Investment in HIV Cure Research and Development in 2019
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a
A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical
After decades of research and advocacy, the Dapivirine Vaginal Ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July, the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in the regulatory process to go forward. Download this podcast to hear five different perspectives on the ring, how it expands HIV prevention options for women, and the most important next steps to bring the ring to women who need it.
Designing a New Generation of HIV Prevention Efficacy Trials
Designing trials to test new HIV prevention modalities remains crucial; high rates of new infections persist in communities all over the world. Even with effective tools becoming more accessible, it’s clear no single option fits every need. But those same options make the design of future trials increasingly complex. Bill Snow, AVAC co-founder and senior advisor, explores this issue in Designing a New Generation of Prevention Efficacy Trials. The report lays out basic concepts in innovations in trial design and an analysis of the implications for advocacy.
A Statement on the Future of HIV Prevention Trials
AVAC’s inaugural Trial Design Academy convened in September 2019. At that meeting, a group of around 20 HIV prevention advocates from across the globe explored technical issues related to trial designs, and engaged with researchers, statisticians and regulators to understand the decisions—which must incorporate input from advocates. As an outcome of this workshop, the group developed a statement of its viewpoints and stances on this new, complex generation of HIV prevention trials—this work was presented at AIDS 2020 Virtual: Advocates’ Perspectives on Next-Generation HIV Prevention Trial Design. Read the consensus statement.